CytRx (CYTR) Selects DK049 for Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities turn lower, as fragile yen remains on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
CytRx Nominates Next Clinical Drug Candidate DK049
December 7, 2015 9:00 AM ESTLOS ANGELES, Dec. 7, 2015 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has selected its next drug, designated DK049, for clinical development in 2016. Â DK049 was created using CytRx's novel LADR (Linker-Activated Drug Release) technology that allows the drug to bind to albumin in the body's bloodstream and controls its release at the site of the tumor. The LADR technology used with DK049 employs a two-stage linker that utilizes both pH sensitivity and acts enzymatically to allow release of its cytotoxic drug... More
CytRx Announces Participation at the 26th Annual Oppenheimer Healthcare Conference
December 3, 2015 9:00 AM ESTLOS ANGELES, Dec. 3, 2015 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Daniel Levitt, MD, PhD, Executive Vice President and Chief Medical Officer, will present a corporate update at the 26th Annual Oppenheimer Healthcare Conference on Tuesday, December 8th at 3:55p.m. Eastern Time. The conference will take place at the Westin Grand Central Hotel in New York, NY.
A live and archived webcast of the presentation will be available on the Company's website at... More
